Peptide Reference
Tesamorelin (Egrifta)
Tesamorelin Acetate
The only FDA-approved growth hormone releasing hormone analog specifically for reducing excess abdominal fat in HIV-associated lipodystrophy.
Status
approved
Category
growth hormone
Typical cost
$600-1200/month
Mechanism
Stimulates endogenous growth hormone release with high specificity for visceral fat reduction. Improves lipid profiles and reduces inflammatory markers associated with lipodystrophy.
Potential benefits
- Reduces visceral fat
- Improves body composition
- Better lipid profiles
- FDA-approved indication
- Preserves lean mass
Reported side effects
- Injection site reactions
- Joint pain
- Muscle aches
- Peripheral edema
- Hyperglycemia risk
Common dosing references
subcutaneous
2mg · Daily
3-6 months
Research notes
Tesamorelin in HIV lipodystrophy
2010
FDA approval based on significant visceral adipose tissue reduction
Regulatory and sourcing notes
FDA-approved (Egrifta) specifically for HIV-associated lipodystrophy. Prescription required.
Prescription only. Specialty pharmacy. Requires HIV diagnosis for insurance coverage.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides